Physician profile
Collin Mccarthy
NPI 1962786103
$4,039.83
in general payments reported to CMS, 2019-2025
15 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $1,145 · 2023: $1,363 · 2024: $529 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,757.12 | 2021-2024 | Xarelto |
| Pfizer INC. | $501.19 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $434.60 | 2021-2024 | Farxiga, Airsupra, Lokelma |
| Abiomed | $370.33 | 2023-2025 | Impella |
| Amgen INC. | $353.29 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $217.95 | 2021-2024 | Camzyos, Eliquis |
| Boston Scientific Corporation | $203.39 | 2021-2025 | Axios |
| Medtronic, INC. | $58.73 | 2021-2023 | Corevalve Evolut R |
| Novo Nordisk INC | $24.99 | 2023 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.95 | 2024 | |
| Getinge USA Sales, LLC | $22.55 | 2025 | Vasoview Hemopro 2 |
| Cardiva Medical, INC. | $20.72 | 2023 | Cardiva Vascade 6/7f Vcs |
| Edwards Lifesciences Corporation | $19.61 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.06 | 2023 | Lifevest |
| Teleflex LLC | $13.35 | 2023 | Vascband |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.